Vibegron - Kyorin/Urovant Sciences

Drug Profile

Vibegron - Kyorin/Urovant Sciences

Alternative Names: KRP-114V; MK-4618

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Kyorin Pharmaceutical; Merck & Co; Urovant Sciences
  • Class Antihypertensives; Antispasmodics; Pyrimidines; Pyrrolidines; Small molecules; Tetrapyrroles
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Overactive bladder
  • Phase I Pain
  • Discontinued Endocrine disorders; Hypertension

Most Recent Events

  • 12 Sep 2018 No development reported - Phase-III for Overactive bladder in Japan (PO)
  • 23 Jul 2018 Phase-I clinical trials in Pain in USA (PO), prior to July 2018 (Urovant Sciences pipeline, July 2018)
  • 23 Jul 2018 Urovant Sciences initiates a phase II trial for Overactive bladder in USA (PO), prior to July 2018 (Urovant Sciences pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top